{"id":"methylprednisolone-po","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia / glucose intolerance"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Insomnia and mood changes"},{"rate":null,"effect":"Increased infection risk"},{"rate":null,"effect":"Osteoporosis (with chronic use)"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Cushingoid features (with chronic use)"}]},"_chembl":{"chemblId":"CHEMBL1697782","moleculeType":"Small molecule","molecularWeight":"472.58"},"_dailymed":{"setId":"151ae26c-bd4e-4582-b67a-7b5baf466953","title":"DYURAL 40 KIT (METHYLPREDNISOLONE ACETATE, LIDOCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE, POVIDINE IODINE, SODIUM CHLORIDE, ISOPROPYL ALCOHOL) KIT [ASCLEMED USA, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylprednisolone is a synthetic glucocorticoid that exerts its anti-inflammatory and immunosuppressive effects by binding to intracellular glucocorticoid receptors, translocating to the nucleus, and modulating gene expression. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and reduced immune cell activation and proliferation. It is commonly used orally (PO) for a wide range of inflammatory and autoimmune conditions.","oneSentence":"Methylprednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:02.804Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, systemic lupus erythematosus)"},{"name":"Allergic reactions and asthma exacerbations"},{"name":"Adrenal insufficiency"},{"name":"Certain hematologic malignancies and lymphomas"},{"name":"Organ transplant rejection prophylaxis"}]},"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT02166463","phase":"PHASE3","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-03-19","conditions":"Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma","enrollment":600},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","enrollment":1875},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT06936566","phase":"PHASE2","title":"MAGIC Ruxolitinib for aGVHD","status":"RECRUITING","sponsor":"John Levine","startDate":"2025-05-14","conditions":"Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects","enrollment":98},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT04862221","phase":"PHASE2","title":"TReatment for ImmUne Mediated PathopHysiology","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2022-02-09","conditions":"Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy","enrollment":163},{"nctId":"NCT05807048","phase":"PHASE2","title":"Daratumumab in STK11 Mutated NSCLC","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2023-06-01","conditions":"Non-small Cell Lung Cancer With STK11/LKB1 Mutation","enrollment":8},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT07245732","phase":"PHASE4","title":"Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares","status":"NOT_YET_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2026-04","conditions":"Rheumatoid Arthritis (RA)","enrollment":220},{"nctId":"NCT04216524","phase":"PHASE2","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-29","conditions":"Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":40},{"nctId":"NCT07197749","phase":"EARLY_PHASE1","title":"Vitamin C With Steroids for Gastrointestinal GVHD","status":"NOT_YET_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2026-06","conditions":"Graft-versus-host-disease (GVHD), Gastrointestinal","enrollment":35},{"nctId":"NCT04438382","phase":"PHASE2","title":"Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-01-07","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Steroid-Refractory Pneumonitis","enrollment":1},{"nctId":"NCT06356571","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-03-17","conditions":"Plasma Cell Myeloma Refractory","enrollment":64},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT03755804","phase":"PHASE2","title":"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2018-12-12","conditions":"Hodgkin Lymphoma","enrollment":232},{"nctId":"NCT03913559","phase":"PHASE2","title":"Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-05-14","conditions":"Acute Lymphoblastic Leukemia","enrollment":5},{"nctId":"NCT07101445","phase":"PHASE4","title":"Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-09-24","conditions":"Multiple Myeloma","enrollment":94},{"nctId":"NCT06097364","phase":"PHASE3","title":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-11-14","conditions":"Follicular Lymphoma (FL)","enrollment":733},{"nctId":"NCT06091865","phase":"PHASE3","title":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-13","conditions":"Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":904},{"nctId":"NCT04884035","phase":"PHASE1","title":"Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma","status":"RECRUITING","sponsor":"Celgene","startDate":"2021-09-15","conditions":"Lymphoma, B-Cell","enrollment":174},{"nctId":"NCT00882895","phase":"PHASE2","title":"Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2009-05-05","conditions":"Lymphoma, Non-Hodgkin","enrollment":18},{"nctId":"NCT07258771","phase":"PHASE4","title":"Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"Berinstein, Jeffrey","startDate":"2026-01-16","conditions":"Ulcerative Colitis Acute","enrollment":110},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT04151082","phase":"PHASE1, PHASE2","title":"High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-16","conditions":"Cranial Nerve Disorder, Head and Neck Carcinoma, Oropharyngeal Carcinoma","enrollment":35},{"nctId":"NCT04629248","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-25","conditions":"Primary Membranous Nephropathy","enrollment":142},{"nctId":"NCT07072585","phase":"PHASE2, PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":"Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma","enrollment":1708},{"nctId":"NCT05761171","phase":"PHASE2","title":"A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2024-01-08","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","enrollment":78},{"nctId":"NCT04104438","phase":"PHASE4","title":"Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant","status":"COMPLETED","sponsor":"Fady M Kaldas, M.D., F.A.C.S.","startDate":"2021-01-15","conditions":"Asses Immunosuppression Modulation on Renal Recovery Post LT","enrollment":71},{"nctId":"NCT05627557","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-03-29","conditions":"Childhood Idiopathic Nephrotic Syndrome","enrollment":85},{"nctId":"NCT04270409","phase":"PHASE3","title":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2020-06-16","conditions":"Plasma Cell Myeloma","enrollment":337},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT01920932","phase":"PHASE2","title":"Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-08-12","conditions":"Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma","enrollment":77},{"nctId":"NCT05136976","phase":"PHASE3","title":"Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2023-06-29","conditions":"Anti-MAG Neuropathy","enrollment":90},{"nctId":"NCT07158476","phase":"PHASE4","title":"Efficacy of Methylprednisolone for Pain Control After ACL Repair","status":"RECRUITING","sponsor":"St. Louis University","startDate":"2025-10-21","conditions":"ACL Surgery, Pain Management","enrollment":90},{"nctId":"NCT06143891","phase":"PHASE3","title":"A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-01-23","conditions":"Chronic Graft Versus Host Disease","enrollment":260},{"nctId":"NCT01624805","phase":"PHASE2","title":"Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-06-25","conditions":"Aplastic Anemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome","enrollment":140},{"nctId":"NCT04479267","phase":"PHASE2","title":"Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2020-08-21","conditions":"Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements","enrollment":8},{"nctId":"NCT06598332","phase":"EARLY_PHASE1","title":"5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD)","status":"WITHDRAWN","sponsor":"Baylor College of Medicine","startDate":"2025-08","conditions":"Graft-Versus-Host Disease(GVHD)","enrollment":""},{"nctId":"NCT07185633","phase":"PHASE2","title":"Study of Gecacitinib-corticosteroid as First-line Therapy for Grade II-IV Acute Graft Versus Host Disease","status":"NOT_YET_RECRUITING","sponsor":"Bin Gu","startDate":"2025-10-01","conditions":"aGVHD","enrollment":25},{"nctId":"NCT07159893","phase":"NA","title":"Inectolizumab With Steroid Optimization in Newly Treated NMOSD","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-09","conditions":"Neuromyelitis Optica, Autoimmune Diseases, Demyelinating Autoimmune Diseases, CNS","enrollment":25},{"nctId":"NCT04824092","phase":"PHASE3","title":"Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2021-05-11","conditions":"Diffuse Large B-cell Lymphoma","enrollment":899},{"nctId":"NCT06412497","phase":"PHASE2","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-06-05","conditions":"Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia","enrollment":60},{"nctId":"NCT05827549","phase":"PHASE2","title":"Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Ho Joon Im","startDate":"2024-04-04","conditions":"Acute Lymphoid Leukemia","enrollment":90},{"nctId":"NCT01303887","phase":"PHASE3","title":"A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2009-10","conditions":"Follicular Lymphoma","enrollment":680},{"nctId":"NCT05567289","phase":"","title":"Precision Medicine for Stem Cell Transplantation","status":"RECRUITING","sponsor":"University of Manchester","startDate":"2023-06-06","conditions":"Haematopoietic Stem Cell Transplantation","enrollment":300},{"nctId":"NCT05303792","phase":"PHASE2","title":"Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-06-09","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma","enrollment":68},{"nctId":"NCT04988256","phase":"EARLY_PHASE1","title":"Cyclosporine Vs Steroids in DRESS","status":"ENROLLING_BY_INVITATION","sponsor":"University of Southern California","startDate":"2021-09-27","conditions":"DRESS Syndrome, Drug-Induced Hypersensitivity Syndrome","enrollment":50},{"nctId":"NCT02378298","phase":"PHASE4","title":"Rituximab (RTX) Therapy in Patients With Active TAO","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2011-12","conditions":"Ophthalmopathy, Thyroid-Associated","enrollment":38},{"nctId":"NCT03792256","phase":"PHASE1","title":"Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2019-04-11","conditions":"Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma","enrollment":12},{"nctId":"NCT02828358","phase":"PHASE2","title":"Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-01","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":78},{"nctId":"NCT04599634","phase":"PHASE1","title":"Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-16","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma","enrollment":11},{"nctId":"NCT03593759","phase":"PHASE3","title":"Cardiac Sarcoidosis Randomized Trial","status":"RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2019-01-15","conditions":"Cardiac Sarcoidosis, Sarcoidosis","enrollment":194},{"nctId":"NCT02889523","phase":"PHASE1, PHASE2","title":"Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2016-10","conditions":"Lymphoma, DLBCL, Follicular Lymphoma","enrollment":214},{"nctId":"NCT04066114","phase":"PHASE1, PHASE2","title":"Treg Modulation With CD28 and IL-6 Receptor Antagonists","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-11","conditions":"Living-Donor Kidney Transplant, Kidney Transplant Recipients","enrollment":24},{"nctId":"NCT03701698","phase":"PHASE2","title":"Ruxolitinib and Steroid As First Line Therapy for Acute GVHD","status":"TERMINATED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2018-11-01","conditions":"Acute GVHD","enrollment":1},{"nctId":"NCT01685268","phase":"PHASE1, PHASE2","title":"A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2012-09","conditions":"Prostate Cancer","enrollment":49},{"nctId":"NCT00557193","phase":"PHASE3","title":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-01-15","conditions":"Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia","enrollment":218},{"nctId":"NCT04933617","phase":"PHASE1","title":"Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-24","conditions":"Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma","enrollment":8},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT02061800","phase":"PHASE1, PHASE2","title":"CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diane George","startDate":"2013-06-03","conditions":"Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)","enrollment":14},{"nctId":"NCT01331018","phase":"PHASE1","title":"Gene Therapy for Fanconi Anemia","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2012-02-22","conditions":"Fanconi Anemia","enrollment":3},{"nctId":"NCT01742338","phase":"PHASE4","title":"Dose of Corticosteroids in COPD","status":"TERMINATED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2012-05-03","conditions":"COPD","enrollment":89},{"nctId":"NCT04098718","phase":"PHASE2","title":"Acute Exacerbations Treated With BenRAlizumab (The ABRA Study)","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2021-03-29","conditions":"Asthma, COPD","enrollment":158},{"nctId":"NCT03371667","phase":"PHASE3","title":"To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-08-16","conditions":"Allogeneic Disease, GVH - Graft Versus Host Reaction, GVHD, Acute","enrollment":102},{"nctId":"NCT01858922","phase":"PHASE2","title":"Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2012-12-19","conditions":"Hodgkin Disease","enrollment":40},{"nctId":"NCT05762640","phase":"PHASE2","title":"Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-03","conditions":"Haemophagocytic Lymphohistiocytosis","enrollment":20},{"nctId":"NCT02294357","phase":"PHASE2","title":"Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib","status":"TERMINATED","sponsor":"Oncotherapeutics","startDate":"2014-12","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT04519476","phase":"PHASE1","title":"Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.","status":"UNKNOWN","sponsor":"Oncotherapeutics","startDate":"2020-11-01","conditions":"Refractory Multiple Myeloma","enrollment":22},{"nctId":"NCT05230680","phase":"PHASE1, PHASE2","title":"Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS)","status":"RECRUITING","sponsor":"Won Seog Kim","startDate":"2022-07-01","conditions":"T Cell Lymphoma","enrollment":41},{"nctId":"NCT04888741","phase":"PHASE2","title":"Methods of T Cell Depletion Trial (MoTD)","status":"UNKNOWN","sponsor":"University of Birmingham","startDate":"2021-02-22","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia","enrollment":400},{"nctId":"NCT02661035","phase":"PHASE2","title":"Allo HSCT Using RIC for Hematological Diseases","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-03-09","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia","enrollment":156},{"nctId":"NCT03003520","phase":"PHASE2","title":"A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-02-28","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":46},{"nctId":"NCT03899337","phase":"PHASE2","title":"A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2019-07-23","conditions":"Richter Syndrome","enrollment":105},{"nctId":"NCT05658692","phase":"PHASE4","title":"Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-10-01","conditions":"Acute Respiratory Distress Syndrome","enrollment":1000},{"nctId":"NCT03286634","phase":"PHASE2","title":"ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016","status":"RECRUITING","sponsor":"National Hospital Organization Nagoya Medical Center","startDate":"2017-04-18","conditions":"Down Syndrome, Acute Lymphoblastic Leukemia, Childhood Cancer","enrollment":60},{"nctId":"NCT03113695","phase":"PHASE1","title":"Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2017-12-20","conditions":"Richter's Syndrome, CLL","enrollment":4},{"nctId":"NCT01451515","phase":"PHASE2","title":"NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-05-25","conditions":"Lymphoblastic Lymphoma","enrollment":23},{"nctId":"NCT05413902","phase":"PHASE4","title":"Multi-Modal Anesthesia Protocol in Pain Management of Patients Undergoing Posterior Lumbar Spinal Fusion Surgery","status":"COMPLETED","sponsor":"University of Puerto Rico","startDate":"2021-04-05","conditions":"Pain Management, Posterior Spinal Fusion","enrollment":100},{"nctId":"NCT04636671","phase":"PHASE3","title":"Methylprednisolone vs. Dexamethasone in COVID-19 Pneumonia (MEDEAS RCT)","status":"COMPLETED","sponsor":"University of Trieste","startDate":"2021-04-14","conditions":"Covid19, Viral Pneumonia Human Coronavirus, Severe Acute Respiratory Syndrome","enrollment":690},{"nctId":"NCT01941589","phase":"PHASE4","title":"Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2013-09","conditions":"Ulcerative Colitis","enrollment":149},{"nctId":"NCT04553003","phase":"PHASE4","title":"Glucocorticosteroid Therapy on Drug-induced Liver Injury: a Prospective Non-randomized Concurrent Control Trial","status":"UNKNOWN","sponsor":"Li Yang","startDate":"2020-08-01","conditions":"Drug-induced Liver Injury","enrollment":80},{"nctId":"NCT03465527","phase":"PHASE2","title":"Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCL","status":"COMPLETED","sponsor":"Kosin University Gospel Hospital","startDate":"2017-04-13","conditions":"Diffuse Large B Cell Lymphoma","enrollment":37},{"nctId":"NCT02293109","phase":"PHASE1","title":"Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma","status":"COMPLETED","sponsor":"Mehrdad Abedi, MD","startDate":"2015-12-17","conditions":"Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Stage I Adult Lymphoblastic Lymphoma","enrollment":10},{"nctId":"NCT05137522","phase":"NA","title":"Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2021-07-01","conditions":"Chidamide, Hemophagocytic Lymphohistiocytosis","enrollment":20},{"nctId":"NCT00630253","phase":"PHASE1, PHASE2","title":"Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2000-02-17","conditions":"Fanconi Anemia","enrollment":31},{"nctId":"NCT02033408","phase":"NA","title":"Manipulating the Microbiome in IBD by Antibiotics and FMT","status":"COMPLETED","sponsor":"Shaare Zedek Medical Center","startDate":"2014-01","conditions":"Exacerbation of Ulcerative Colitis, Ulcerative Colitis, Active Severe, Crohn's Colitis","enrollment":28},{"nctId":"NCT02776059","phase":"PHASE2","title":"Pegfilgrastim in Patients With Alcoholic Hepatitis","status":"COMPLETED","sponsor":"Timothy Morgan, MD","startDate":"2017-01-21","conditions":"Alcoholic Hepatitis","enrollment":34},{"nctId":"NCT01790594","phase":"PHASE2","title":"Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-02","conditions":"Simultaneous Kidney and Pancreas Transplantation","enrollment":46},{"nctId":"NCT04374929","phase":"NA","title":"Subcostal Temporary Extracardiac Pacing II Study","status":"COMPLETED","sponsor":"AtaCor Medical, Inc.","startDate":"2020-07-28","conditions":"Conduction Defect","enrollment":7},{"nctId":"NCT03797872","phase":"PHASE4","title":"Psoriatic Oligoarthritis Intervention With Symptomatic thErapy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-04-17","conditions":"Psoriatic Arthritis","enrollment":1},{"nctId":"NCT03283202","phase":"PHASE1","title":"Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-10-04","conditions":"Diffuse B-Cell Lymphoma","enrollment":35},{"nctId":"NCT02472054","phase":"PHASE1, PHASE2","title":"Treatment of Familiar Lymphohistiocytosis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-06-29","conditions":"Hemophagocytic Lymphohistiocytosis (HLH)","enrollment":29},{"nctId":"NCT04617561","phase":"PHASE4","title":"Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2020-11-01","conditions":"Hepatitis, Autoimmune, Primary Biliary Cholangitis","enrollment":90},{"nctId":"NCT01856257","phase":"PHASE2","title":"Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-07","conditions":"Primary Renal Allograft Candidate, Kidney Transplantation","enrollment":71},{"nctId":"NCT00671658","phase":"PHASE2","title":"Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-11","conditions":"Leukemia, Acute Lymphoblastic Leukemia","enrollment":220},{"nctId":"NCT02935738","phase":"NA","title":"Prednisolone Improves IVF Outcomes in Men With Anti-sperm Antibodies","status":"COMPLETED","sponsor":"Barz IVF Center for Infertility Treatment and Embryo Research","startDate":"2014-10","conditions":"Reproductive Sterility","enrollment":241}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":71,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"methylprednisolone PO","genericName":"methylprednisolone PO","companyName":"Rennes University Hospital","companyId":"rennes-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methylprednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, systemic lupus erythematosus), Allergic reactions and asthma exacerbations, Adrenal insufficiency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}